未登录

L

Linda Härmark

Universidad Costa Rica

H指数:26

被引数:1,970

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Toward a Framework for Case Identification in Pharmacovigilance: Not All Reports are Created Equal

药物警戒案例识别框架的构建：并非所有报告都同等重要

IF3.8

2026-10-230

OAAI

Global Perspective on the Evolution and Future of Pharmacovigilance: Deliverables from the 24th Annual Meeting of the International Society of Pharmacovigilance Celebrating 25 Years of Excellence

全球药物警戒的演变与未来：国际药物警戒学会第24届年会暨25周年庆典成果

IF3.8

2026-06-020

PREAI

Development, assessment and educational impact of a blended e-learning training program on pharmacovigilance implemented in four African countries

FRONTIERS IN MEDICINE

IF3

2024-04-171

OAAI

Funding and financial sustainability of pharmacovigilance: suggested models for funding pharmacovigilance in resource-limited African countries

THERAPEUTIC ADVANCES IN DRUG SAFETY

IF3.4

2023-07-242

OAAI

Development and validation of a machine-learning algorithm to predict the relevance of scientific articles within the field of teratology

REPRODUCTIVE TOXICOLOGY

IF2.8

2022-10-012

OAAI

Factors Contributing to Best Practices for Patient Involvement in Pharmacovigilance in Europe: A Stakeholder Analysis

IF3.8

2022-08-2511

OAAI

Pharmacovigilance Data as a Trigger to Identify Antimicrobial Resistance and Inappropriate Use of Antibiotics: A Study Using Reports from The Netherlands Pharmacovigilance Centre

ANTIBIOTICS-BASEL

IF4.6

2021-12-096

OA

Motives to Report Adverse Drug Reactions to the National Agency: A Survey Study among Healthcare Professionals and Patients in Croatia, The Netherlands, and the UK

IF3.8

2021-08-086

OAAI

Online information discrepancies regarding safety of medicine use during pregnancy and lactation: an IMI ConcePTION study

EXPERT OPINION ON DRUG SAFETY

IF3.1

2021-06-0814

OAAI

Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands (vol 53, pg 861, 2020)

IF3.8

2020-07-020

OAAI

Evaluation of a Web-Based, 'Purchase Event' Intensive Monitoring Method for Pharmacovigilance of Natural Health Products: Lessons and Insights from Development Work in New Zealand

IF3.8

2020-06-281

PREAI

Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands

IF3.8

2020-05-164

OAAI

Fifteen years of patient reporting -what have we learned and where are we heading to?

EXPERT OPINION ON DRUG SAFETY

IF3.1

2019-05-1620

PREAI

Recommendations on the Use of Mobile Applications for the Collection and Communication of Pharmaceutical Product Safety Information: Lessons from IMI WEB-RADR

IF3.8

2019-03-2540

OAAI

Collaboration between patient and pharmacovigilance organizations to gain insight into adults' experiences with drug use and ADRs for the treatment of ADHD

EXPERT OPINION ON DRUG SAFETY

IF3.1

2019-03-142

PREAI

What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects

IF3.8

2018-06-1343

OAAI

Desogestrel and panic attacks - a new suspected adverse drug reaction reported by patients and health care professionals on spontaneous reports

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2018-05-245

OAAI

Characteristics, Quality and Contribution to Signal Detection of Spontaneous Reports of Adverse Drug Reactions Via the WEB-RADR Mobile Application: A Descriptive Cross-Sectional Study

IF3.8

2018-05-1423

OAAI

First experiences with a tool to measure the level of clinical information present in adverse drug reaction reports

EXPERT OPINION ON DRUG SAFETY

IF3.1

2017-11-2014

OA

Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre

IF3.8

2017-09-2036

OAAI